Bio-Rad Laboratories Company Profile (NYSE:BIO)

About Bio-Rad Laboratories

Bio-Rad Laboratories logoBio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Company's Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Company's Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. Bio-Rad sells over 8,000 products and services to a client base consisting of scientific research, healthcare, education and government customers around the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NYSE
  • Symbol: BIO
  • CUSIP: 09057220
Key Metrics:
  • Previous Close: $191.85
  • 50 Day Moving Average: $187.19
  • 200 Day Moving Average: $168.46
  • 52-Week Range: $29,541,000.00 - $123.68
  • Trailing P/E Ratio: 58.14
  • Foreward P/E Ratio: 64.86
  • P/E Growth: -17.66
  • Market Cap: $5.71B
  • Outstanding Shares: 29,541,000
  • Beta: 0.89
Profitability:
  • Net Margins: 4.75%
  • Return on Equity: 3.79%
  • Return on Assets: 2.56%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 4.18%
  • Quick Ratio: 2.92%
Additional Links:
Companies Related to Bio-Rad Laboratories:

Analyst Ratings

Consensus Ratings for Bio-Rad Laboratories (NYSE:BIO) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $200.00 (3.48% upside)

Analysts' Ratings History for Bio-Rad Laboratories (NYSE:BIO)
Show:
DateFirmActionRatingPrice TargetDetails
1/18/2017Deutsche Bank AGReiterated RatingHold$195.00View Rating Details
12/4/2016Jefferies Group LLCReiterated RatingBuy$225.00View Rating Details
10/12/2016CL KingInitiated CoverageBuy$180.00View Rating Details
11/4/2015Leerink SwannBoost Price Target$143.00 -> $149.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Bio-Rad Laboratories (NYSE:BIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
11/1/2016Q316$0.51$0.62$480.60 million$508.75 millionViewN/AView Earnings Details
8/3/2016Q2$1.13$0.61$497.80 million$516.80 millionViewN/AView Earnings Details
5/5/2016Q1$0.60$0.42$463.90 million$471.20 millionViewN/AView Earnings Details
2/25/2016Q415$1.27$1.68$570.80 million$570.56 millionViewListenView Earnings Details
11/3/2015Q315$0.54$0.59$495.55 million$469.96 millionViewN/AView Earnings Details
8/6/2015Q215$0.78$0.97$494.85 million$506.10 millionViewN/AView Earnings Details
5/5/2015Q115$0.33$0.61$474.60 million$472.80 millionViewN/AView Earnings Details
2/26/2015Q414$1.18$1.34$593.41 million$598.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.86$0.39$525.40 million$530.64 millionViewN/AView Earnings Details
8/5/2014Q214$0.95$1.09$537.58 million$536.80 millionViewN/AView Earnings Details
5/6/2014Q114$0.80$0.23$515.00 million$509.30 millionViewN/AView Earnings Details
2/27/2014Q413$1.42$1.04$586.67 million$602.60 millionViewListenView Earnings Details
11/7/2013Q313$0.91($0.25)$529.02 million$505.10 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.25$1.20$532.60 million$525.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.03$0.68$506.34 million$499.70 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.33$1.65$558.68 million$573.80 millionViewN/AView Earnings Details
11/6/2012Q312$1.14$1.48$507.79 million$498.70 millionViewN/AView Earnings Details
8/7/2012$1.19$1.69ViewN/AView Earnings Details
5/1/2012$1.02$1.09ViewN/AView Earnings Details
2/23/2012$1.67$2.08ViewN/AView Earnings Details
11/1/2011$1.53$1.61ViewN/AView Earnings Details
8/2/2011$1.47$1.41ViewN/AView Earnings Details
5/3/2011$1.32$1.16ViewN/AView Earnings Details
2/24/2011$1.35$2.41ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Rad Laboratories (NYSE:BIO)
Current Year EPS Consensus Estimate: $2.75 EPS
Next Year EPS Consensus Estimate: $2.98 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.72$0.85$0.79
Q2 20163$1.01$1.12$1.07
Q3 20162$0.51$0.84$0.68
Q4 20162$0.87$1.55$1.21
Q1 20171$0.41$0.41$0.41
Q2 20171$0.95$0.95$0.95
Q3 20171$0.57$0.57$0.57
Q4 20171$0.82$0.82$0.82
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bio-Rad Laboratories (NYSE:BIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bio-Rad Laboratories (NYSE:BIO)
Insider Ownership Percentage: 28.38%
Institutional Ownership Percentage: 64.29%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2016James R. StarkVPSell1,299$171.42$222,674.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bio-Rad Laboratories (NYSE:BIO)
DateHeadline
investornewswire.com logoBio-Rad Laboratories, Inc. (NYSE:BIO) Strong Sell Recommendations At 0 - Investor Newswire (NYSE:BIO)
www.investornewswire.com - February 18 at 3:48 PM
News IconLevels in Review for Bio-Rad Laboratories, Inc. (NYSE:BIO) - Davidson Register (NYSE:BIO)
davidsonregister.com - February 17 at 3:31 PM
finance.yahoo.com logoNew Strong Sell Stocks for February 17th (NYSE:BIO)
finance.yahoo.com - February 17 at 10:37 AM
News IconInvestor Watch on Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - BVN (NYSE:BIO)
bvnewsjournal.com - February 16 at 5:32 AM
News IconJames Wagstaffe Defeated Bio-Rad With Storytelling | Corporate ... - Corporate Counsel (registration) (NYSE:BIO)
www.corpcounsel.com - February 16 at 5:32 AM
nasdaq.com logoTimesSquare Capital Management, LLC Buys Signature Bank, Bio-Rad Laboratories, Progressive, ... - Nasdaq (NYSE:BIO)
www.nasdaq.com - February 16 at 5:32 AM
News IconInfectious Disease Diagnostics Market Trends and Segments 2016-2026 (NYSE:BIO)
reports.pr-inside.com - February 15 at 2:33 AM
News IconSexually Transmitted Diseases (STDs) Testing Market Strategic Moves and Developments (NYSE:BIO)
empowerednews.net - February 15 at 2:33 AM
News IconFederal Whistleblowers Law Collide With The Attorney-Client Privilege: The Bio-Rad Case Study (NYSE:BIO)
www.jdsupra.com - February 15 at 2:33 AM
News IconJames Wagstaffe Defeated Bio-Rad With Storytelling (NYSE:BIO)
www.therecorder.com - February 14 at 9:28 PM
prnewswire.com logoMolecular Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025 (NYSE:BIO)
www.prnewswire.com - February 14 at 4:28 PM
News IconMetadata Plays Key Role in $10.8 Million Whistleblower Lawsuit Verdict: eDiscovery Case Law (NYSE:BIO)
www.ediscovery.co - February 14 at 2:25 AM
News IconWorldwide Imaging Biomarkers Market by Type & Application 2016 – 2023 (NYSE:BIO)
www.medgadget.com - February 13 at 4:25 PM
bizjournals.com logoWith $2 billion in sales, 8,000 employees and stock that's leaped 48% in 12 mos., why have you never heard of this East Bay biotech? (NYSE:BIO)
www.bizjournals.com - February 13 at 4:24 PM
News IconBio-Rad Laboratories, Inc. (NYSE:BIO) Investor Investigation over possible Violations of Securities Laws (NYSE:BIO)
www.satprnews.com - February 12 at 3:57 PM
News IconBio-Rad Laboratories, Inc. (NYSE:BIO) Investor Investigation over possible Violations of Securities Laws (NYSE:BIO)
www.satprnews.com - February 12 at 3:57 PM
News IconSADIF Analytics releases new summary due diligence report for Bio Rad Laboratories Inc ($BIO). (NYSE:BIO)
reports.pr-inside.com - February 11 at 3:56 PM
News IconBio-Rad Verdict Could Spur GC Whistleblower Claims (NYSE:BIO)
www.nationallawjournal.com - February 11 at 3:56 PM
marketnewsvideo.com logoShort Interest Falls 27.3% For BIO (NYSE:BIO)
www.marketnewsvideo.com - February 11 at 3:56 PM
News IconBio-Rad Verdict Could Spur GC Whistleblower Claims - The National Law Journal (registration) (NYSE:BIO)
www.nationallawjournal.com - February 10 at 3:24 PM
News IconUPDATE: Jury Awards Former General Counsel $10.8 Million In Damages (NYSE:BIO)
www.jdsupra.com - February 9 at 9:07 PM
News IconCalifornia Federal Jury Awards Former General Counsel $10.8 Million... (NYSE:BIO)
www.natlawreview.com - February 9 at 4:04 PM
News IconMarket Study on Expected Growth for Clinical Electrophoresis Market (NYSE:BIO)
www.medgadget.com - February 8 at 9:06 PM
News IconMagistrate Judge Rules SEC’s Attorney-Conduct Rules Preempt State Law (NYSE:BIO)
www.jdsupra.com - February 8 at 9:06 PM
News IconShares in the Spotlight: Bio-Rad Laboratories, Inc. (NYSE:BIO) - Sherwood Daily (NYSE:BIO)
sherwooddaily.com - February 8 at 4:04 PM
gurufocus.com logoWinslow Asset Management Inc Buys Bio-Rad Laboratories, Fossil Group, Dell Technologies, Sells Tetra Tech - GuruFocus.com (NYSE:BIO)
www.gurufocus.com - February 8 at 4:04 PM
News Icon5 Takeaways From Bio-Rad's Trial Loss, and Its Ousted GC's Win (NYSE:BIO)
www.corpcounsel.com - February 7 at 9:54 PM
News IconFCPA whistleblower: Former Bio-Rad GC awarded $10 million for retaliatory firing (NYSE:BIO)
www.fcpablog.com - February 7 at 4:53 PM
News IconAce Laboratories, Inc. Announces Licensing of Resveratrol Patents (NYSE:BIO)
www.bio-medicine.org - February 7 at 4:53 PM
News IconBio-Rad Launches ChemiDoc™ MP Imaging System (NYSE:BIO)
www.the-scientist.com - February 7 at 4:53 PM
News IconCalifornia Jury Awards Former Bio-Rad Counsel $8M in Sarbanes-Oxley Whistleblower Case (NYSE:BIO)
www.natlawreview.com - February 7 at 4:53 PM
News IconFormer Bio-Rad GC Asks Jury for $35 Million in Damages (NYSE:BIO)
www.nationallawjournal.com - February 6 at 8:56 PM
News IconOusted Bio-Rad GC Wins Whistleblower Case (NYSE:BIO)
www.therecorder.com - February 6 at 8:56 PM
News IconCoxsackievirus Diagnostics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019 (NYSE:BIO)
www.medgadget.com - February 6 at 3:56 PM
News IconToxicology Laboratories Market is Expected to Gain Popularity Across the Globe (NYSE:BIO)
www.medgadget.com - February 3 at 4:03 PM
News IconBio-Rad Trial Witnesses Claim Outburst, Obstruction by Ex-GC - InsideCounsel (NYSE:BIO)
www.insidecounsel.com - February 3 at 2:11 AM
News IconDavis Polk Partner Says Bio-Rad GC Kept Pushing Flimsy Claims - The American Lawyer (NYSE:BIO)
www.americanlawyer.com - February 3 at 2:11 AM
News IconDavis Polk Partner Says Bio-Rad GC Kept Pushing Flimsy Claims (NYSE:BIO)
www.therecorder.com - February 2 at 9:09 PM
News IconBio-Rad Builds Case That Ex-GC Was 'Out of Control' (NYSE:BIO)
www.therecorder.com - February 2 at 2:09 AM
News IconBio-Rad Trial Witnesses Claim Outburst, Obstruction by Ex-GC (NYSE:BIO)
www.therecorder.com - February 1 at 2:14 AM
4-traders.com logoBio Rad Laboratories : Reagents for automatic glycated hemoglobin analyzer D-10" produced by Bio-Rad Laboratories (NYSE:BIO)
www.4-traders.com - January 31 at 4:10 PM
News IconChecking the Levels on Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - The Tribune (NYSE:BIO)
lakecitytribune.com - January 30 at 3:46 PM
News IconBio-Rad's FCPA Lawyer Details Run-In With Ousted GC - The Recorder (NYSE:BIO)
www.therecorder.com - January 27 at 3:57 PM
wsj.com logoCorruption Currents: Trump, Putin to Discuss Sanctions on Russia (NYSE:BIO)
blogs.wsj.com - January 27 at 3:57 PM
News IconVolatility Numbers in View for Bio-Rad Laboratories, Inc. (NYSE:BIO) - The Tribune (NYSE:BIO)
lakecitytribune.com - January 26 at 4:34 PM
law360.com logoBio-Rad GC’s Corruption Report Baseless, Atty Testifies (NYSE:BIO)
www.law360.com - January 26 at 2:32 AM
News IconBio-Rad's FCPA Lawyer Details Run-In With Ousted GC (NYSE:BIO)
www.therecorder.com - January 25 at 2:30 AM
News IconOutside Counsel Complained About Bio-Rad GC, CEO Says | The ... - The American Lawyer (NYSE:BIO)
www.americanlawyer.com - January 24 at 9:30 PM
News IconValue Composite Score Update on Bio-Rad Laboratories, Inc. (NYSE:BIO) - The Tribune (NYSE:BIO)
lakecitytribune.com - January 24 at 1:21 AM
News IconOutside Counsel Complained About Bio-Rad GC, CEO Says - The American Lawyer (NYSE:BIO)
www.americanlawyer.com - January 24 at 1:21 AM

Social

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Where is Bio-Rad Laboratories' stock going? Where will Bio-Rad Laboratories' stock price be in 2017?

3 analysts have issued twelve-month price targets for Bio-Rad Laboratories' stock. Their predictions range from $180.00 to $225.00. On average, they anticipate Bio-Rad Laboratories' share price to reach $200.00 in the next twelve months.

When will Bio-Rad Laboratories announce their earnings?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

Who owns Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include Atlanta Capital Management Co. L L C (6.04%), State Street Corp (1.82%), NWQ Investment Management Company LLC (1.37%), Levin Capital Strategies L.P. (0.91%), Thompson Siegel & Walmsley LLC (0.71%) and Russell Investments Group Ltd. (0.68%).

Who sold Bio-Rad Laboratories stock? Who is selling Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Martingale Asset Management L P, NWQ Investment Management Company LLC, Thompson Siegel & Walmsley LLC, Highland Capital Management LP, Atlanta Capital Management Co. L L C, AQR Capital Management LLC and Guggenheim Capital LLC.

Who bought Bio-Rad Laboratories stock? Who is buying Bio-Rad Laboratories stock?

Bio-Rad Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., FMR LLC, Tudor Investment Corp Et Al, Perceptive Advisors LLC, Lodge Hill Capital LLC, Employees Retirement System of Texas, Teachers Retirement System of The State of Kentucky and Folger Hill Asset Management LP.

How do I buy Bio-Rad Laboratories stock?

Shares of Bio-Rad Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bio-Rad Laboratories stock cost?

One share of Bio-Rad Laboratories stock can currently be purchased for approximately $193.27.

Bio-Rad Laboratories (NYSE:BIO) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Earnings History Chart

Earnings by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Dividend History Chart

Dividend Payments by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Last Updated on 2/20/2017 by MarketBeat.com Staff